Department of Dermatology and Allergy, University Hospital of LMU, Frauenlobstr. 9-11, 80337, Munich, Germany.
Syst Rev. 2019 Oct 11;8(1):237. doi: 10.1186/s13643-019-1156-8.
Actinic keratoses (AK) are common precancerous lesions of the skin due to cumulative sun exposure. A variety of interventions are available for the treatment; however, the majority of randomised controlled trials (RCTs) and meta-analyses focus on short-term efficacy outcomes. This network meta-analysis aims to investigate the long-term (> 12 months) efficacy of interventions for AK.
To identify relevant studies, we will perform a systematic literature research in MEDLINE, Embase, and CENTRAL and hand-search pertinent trial registers. Two authors will independently screen titles and abstracts for eligibility. We will include RCTs with an inter-individual (parallel arm) design. The study population includes patients with a clinical or histopathologic diagnosis of AK. Eligibility will be restricted to the following interventions: surgical approaches, cryosurgery, ablative laser treatment, topical drug treatment with 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, or photodynamic therapy. As outcomes, we will consider the following endpoints: (1) the participant complete clearance rate, (2) the participant partial clearance rate, (3) the lesion-specific clearance, (4) the mean lesion reduction per patient, and (5) the number of withdrawals due to adverse events after at least 12 months after the end of treatment. Monotherapy or placebo will serve as a comparison. Estimates of effects from individual studies will be pooled using a random-effects model. Heterogeneity will be evaluated based on I and chi-square test. The risk of bias will be estimated with the Cochrane Risk of Bias Tool by two review authors independently. The quality of evidence of the outcomes will be assessed with the GRADE approach. A network meta-analysis will be performed to combine direct and indirect evidence from the included RCTs.
The potential of interventions to achieve a sustained clearance of AK has not been assessed to date. To investigate the long-term efficacy of interventions is important as the natural disease course is highly variable and relapses occur frequently even after initial lesion clearance. This review will help to set a framework for clinical decision making in patients with AK.
CRD42018095903 (PROSPERO).
光化性角化病(AK)是由于长期暴露在阳光下导致的常见皮肤癌前病变。有多种干预措施可用于治疗,但大多数随机对照试验(RCT)和荟萃分析都集中在短期疗效上。本网络荟萃分析旨在研究 AK 的长期(>12 个月)疗效。
为了确定相关研究,我们将在 MEDLINE、Embase 和 CENTRAL 中进行系统文献检索,并对相关试验登记册进行手工检索。两名作者将独立筛选标题和摘要以确定其是否符合入选标准。我们将纳入个体间(平行臂)设计的 RCT。研究人群包括临床或组织病理学诊断为 AK 的患者。入选标准将限于以下干预措施:手术方法、冷冻疗法、消融性激光治疗、5-氟尿嘧啶、咪喹莫特、 Ingenol mebutate、双氯芬酸或光动力疗法的局部药物治疗。作为结局,我们将考虑以下终点:(1)参与者完全清除率,(2)参与者部分清除率,(3)病变特异性清除率,(4)每位患者的平均病变减少率,(5)治疗结束后至少 12 个月因不良事件而退出的人数。单药治疗或安慰剂将作为对照。将使用随机效应模型对来自个体研究的估计值进行汇总。基于 I 平方和卡方检验评估异质性。两名审查作者将独立使用 Cochrane 偏倚风险工具评估偏倚风险。使用 GRADE 方法评估结局的证据质量。将进行网络荟萃分析,以合并纳入 RCT 的直接和间接证据。
迄今为止,尚未评估干预措施实现 AK 持续清除的潜力。研究干预措施的长期疗效很重要,因为疾病的自然病程变化很大,即使在初始病变清除后,也经常复发。本综述将有助于为 AK 患者的临床决策制定框架。
CRD42018095903(PROSPERO)。